{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T09:32:10Z","timestamp":1781343130194,"version":"3.54.1"},"reference-count":304,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.00557","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T04:46:03Z","timestamp":1522817163000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":52,"title":["Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines\/Cytokines"],"prefix":"10.3389","volume":"9","author":[{"given":"Michael R.","family":"Pranzatelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,4,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.spen.2017.08.001","article-title":"Promise, progress, and pitfalls in the search for CNS biomarkers in neuroimmunological diseases: a role for CSF immunophenotyping","volume":"24","author":"Bielekova","year":"2017","journal-title":"Sem Pediatr Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.clim.2015.04.006","article-title":"Stratified medicine in inflammatory disorders: from theory to practice","volume":"161","author":"Arron","year":"2015","journal-title":"Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e48370","DOI":"10.1371\/journal.pone.0048370","article-title":"Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation","volume":"7","author":"Bielekova","year":"2012","journal-title":"PLoS One"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1177\/1352458514564482","article-title":"Subclinical central inflammation is risk for RIS and CIS conversion to MS","volume":"21","author":"Rossi","year":"2015","journal-title":"Mult Scler"},{"key":"B5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/cyto.a.22439","article-title":"Flow cytometry applications for the analysis of chemokine receptor expression and function","volume":"85","author":"Anselmo","year":"2014","journal-title":"Cytometry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nri.2016.123","article-title":"Cytokine networks in neuroinflammation","volume":"17","author":"Becher","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.immuni.2009.09.010","article-title":"Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology","volume":"31","author":"Ransohoff","year":"2009","journal-title":"Immunity"},{"key":"B8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jns.2013.01.011","article-title":"Cytokines, cytokine antagonists, and soluble adhesion molecules in pediatric OMS and other neuroinflammatory disorders","volume":"326","author":"Pranzatelli","year":"2013","journal-title":"J Neurol Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e81007","DOI":"10.1371\/journal.pone.0081007","article-title":"Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis","volume":"8","author":"Edwards","year":"2013","journal-title":"PLoS One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.bbadis.2010.07.019","article-title":"The blood-brain barrier, chemokines and multiple sclerosis","volume":"1812","author":"Holman","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"B11","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1146\/annurev-immunol-032713-120145","article-title":"Chemokines and chemokine receptors: positioning cells for host defenses and immunity","volume":"32","author":"Griffith","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3389\/fncel.2014.00154","article-title":"Chemokines in the balance: maintenance of homeostasis and protection at CNS barriers","volume":"8","author":"Williams","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1042\/CS20130497","article-title":"Cytokine networking of innate immunity cells: a potential target of therapy","volume":"126","author":"Striz","year":"2014","journal-title":"Clin Sci (Lond)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.cyto.2015.10.001","article-title":"CSF cytokines\/chemokines as biomarkers in neuroinflammatory CNS disorders: a systematic review","volume":"77","author":"Kothur","year":"2016","journal-title":"Cytokine"},{"key":"B15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1586\/1744666X.2015.1024110","article-title":"GM-CSF as a target in inflammatory\/autoimmune disease: current evidence and future therapeutic potential","volume":"11","author":"Hamilton","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jns.2006.05.049","article-title":"Cytokines and chemokines in cerebrospinal fluid and serum of adult patients with acute disseminated encephalomyelitis","volume":"247","author":"Franciotta","year":"2006","journal-title":"J Neurol Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1179\/1743132812Y.0000000074","article-title":"Proinflammatory cytokines in serum and cerebrospinal fluid of CIDP patients","volume":"34","author":"Rentzos","year":"2012","journal-title":"Neurol Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1744666x.2017.1279055","article-title":"IL-23 blockade for Crohns disease: next generation of anti-cytokine therapy","volume":"13","author":"Furfaro","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","article-title":"The interleukin-1 family: back to the future","volume":"39","author":"Garlanda","year":"2013","journal-title":"Immunity"},{"key":"B20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.cyto.2015.01.030","article-title":"Interleukin 12 (IL-12) family cytokines: role in immune pathogenesis and treatment of CNS autoimmune diseases","volume":"75","author":"Sun","year":"2015","journal-title":"Cytokine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00281-016-0612-y","article-title":"TNF superfamily cytokines in the promotion of Th9 differentiation and immunopathology","volume":"39","author":"Meylan","year":"2017","journal-title":"Semin Immunopathol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","article-title":"TNF biology, pathogenic mechanism and emerging therapeutic strategies","volume":"12","author":"Kalliolias","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cytogfr.2012.07.002","article-title":"Emerging role of interleukin-22 in autoimmune diseases","volume":"24","author":"Pan","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"B24","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1586\/1744666X.2014.894886","article-title":"The CXCL8\/IL-8 chemokine family and its receptors in inflammatory diseases","volume":"10","author":"Russo","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1172\/JCI58644","article-title":"Innate immunity in the central nervous system","volume":"122","author":"Ransohoff","year":"2012","journal-title":"J Clin Invest"},{"key":"B26","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"5979","DOI":"10.1111\/bph.13353","article-title":"The concise guide to PHARMACOLOGY 2015\/2016: catalytic receptors","volume":"172","author":"Alexander","year":"2015","journal-title":"Br J Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.clim.2016.01.015","article-title":"Early BAFF receptor blockade mitigates murine Sj\u00f6gren\u2019s syndrome: concomitant targeting of CXCL13 and the BAFF receptor prevents salivary hypofunction","volume":"164","author":"Sharma","year":"2016","journal-title":"Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrrheum.2016.18","article-title":"The BAFFling effects of rituximab in lupus: danger ahead?","volume":"12","author":"Ehrenstein","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.4049\/jimmunol.1303435","article-title":"A soluble form of IL-27R\u03b1 is a natural IL-27 antagonist","volume":"192","author":"Dietrich","year":"2014","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"9511","DOI":"10.1073\/pnas.171303198","article-title":"A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist","volume":"98","author":"Xu","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B32","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/cpt.782","article-title":"The soluble interleukin 6 receptor: advanced therapeutic options in inflammation","volume":"102","author":"Rose-John","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1007\/s13311-015-0385-3","article-title":"Neuroinflammation: ways in which the immune system affects the brain","volume":"12","author":"Ransohoff","year":"2015","journal-title":"Neurotherapeutics"},{"key":"B34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1074-7613(00)80165-X","article-title":"Chemokines: a new classification system and their role in immunity","volume":"12","author":"Zlotnik","year":"2000","journal-title":"Immunity"},{"key":"B35","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1089\/jir.2012.0132","article-title":"Pediatric reference ranges for proinflammatory and anti-inflammatory cytokines in cerebrospinal fluid and serum by multiplexed immunoassay","volume":"33","author":"Pranzatelli","year":"2013","journal-title":"J Interferon Cytokine Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","article-title":"Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/17460441.2017.1268597","article-title":"Designing small molecule CXCR3 antagonists","volume":"12","author":"Pease","year":"2017","journal-title":"Expert Opin Drug Discov"},{"key":"B38","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1089\/jir.2016.0076","article-title":"Mucosal chemokines","volume":"37","author":"Hern\u00e1ndez-Ruiz","year":"2017","journal-title":"J Interferon Cytokine Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/00024382-199509000-00001","article-title":"The role of CXC chemokines as regulators of angiogenesis","volume":"4","author":"Strieter","year":"1995","journal-title":"Shock"},{"key":"B40","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.molmed.2010.01.003","article-title":"Chemokines and chemokine receptors: new insights into cancer-related inflammation","volume":"16","author":"Lazennec","year":"2010","journal-title":"Trends Mol Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1124\/pr.55.4.4","article-title":"International union of pharmacology committee on receptor nomenclature and drug classification. XXXVIII. Update on terms and symbols in quantitative pharmacology","volume":"55","author":"Neubig","year":"2003","journal-title":"Pharmacol Rev"},{"key":"B42","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3390\/ijms18020342","article-title":"Mechanisms of regulation of the chemokine-receptor network","volume":"18","author":"Stone","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3389\/fnagi.2017.00148","article-title":"Role of atypical chemokine receptors in microglial activation and polarization","volume":"9","author":"Salvi","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1111\/bph.13182","article-title":"An atypical addition to the chemokine receptor nomenclature: IUPHAR review 15","volume":"172","author":"Bacheleries","year":"2015","journal-title":"Br J Pharmacol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1042\/BST20120246","article-title":"Atypical chemokine receptors: from silence to sound","volume":"41","author":"Cancellieri","year":"2013","journal-title":"Biochem Soc Trans"},{"key":"B46","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejphar.2014.02.007","article-title":"Internalization of the chemokine receptor CCR4 can be evoked by orthosteric and allosteric antagonists","volume":"729","author":"Ajram","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1155\/2006\/694283","article-title":"Chemokine receptors as biomarkers in multiple sclerosis","volume":"22","author":"Fox","year":"2006","journal-title":"Dis Markers"},{"key":"B48","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1046\/j.1365-2249.2002.01947.x","article-title":"T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking","volume":"129","author":"Kivis\u00e4kk","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.brainresrev.2004.07.021","article-title":"Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases","volume":"48","author":"Cartier","year":"2005","journal-title":"Brain Res Brain Res Rev"},{"key":"B50","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1084\/jem.20041674","article-title":"BAFF is produced by astrocytes and upregulated in multiple sclerosis lesions and primary central nervous system lymphoma","volume":"210","author":"Krumbholz","year":"2005","journal-title":"J Exp Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2174\/1389203711314010004","article-title":"Neuron-microglia interaction in neuroinflammation","volume":"14","author":"Suzumura","year":"2013","journal-title":"Curr Protein Pept Sci"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e0161656","DOI":"10.1371\/journal.pone.0161656","article-title":"Utility of CSF cytokine\/chemokines as markers of active intrathecal inflammation: comparison of demyelinating, anti-NMDAR and enteroviral encephalitis","volume":"11","author":"Kothur","year":"2016","journal-title":"PLoS One"},{"key":"B53","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/ana.20049","article-title":"Expression of CCR7 in multiple sclerosis: implications for CNS immunity","volume":"55","author":"Kivis\u00e4kk","year":"2004","journal-title":"Ann Neurol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.neuron.2015.05.019","article-title":"Dealing with danger in the CNS: the response of the immune system to injury","volume":"87","author":"Gadini","year":"2015","journal-title":"Neuron"},{"key":"B55","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.cyto.2014.09.011","article-title":"T cell subsets and their signature cytokines in autoimmune and inflammatory diseases","volume":"74","author":"Raphael","year":"2015","journal-title":"Cytokine"},{"key":"B56","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cyto.a.22348","article-title":"T helper cells plasticity in inflammation","volume":"85","author":"Cosmi","year":"2014","journal-title":"Cytometry A"},{"key":"B57","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cellimm.2014.04.013","article-title":"\u03b3\u03b4 T cell subsets play opposing roles in regulating experimental autoimmune encephalitis","volume":"290","author":"Blink","year":"2014","journal-title":"Cell Immunol"},{"key":"B58","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/ar3906","article-title":"B-cell targeted therapeutics in clinical development","volume":"15","author":"Bl\u00fcml","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B59","doi-asserted-by":"publisher","first-page":"200211","DOI":"10.1093\/brain\/awh680","article-title":"Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment","volume":"129","author":"Krumbholz","year":"2006","journal-title":"Brain"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2017.07.012","article-title":"Dendritic cell recruitment and activation in autoimmunity","author":"Sozzani","year":"2017","journal-title":"J Autoimmun"},{"key":"B61","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jneuroim.2012.08.009","article-title":"Characterization of natural killer cells in paired CSF and blood samples during neuroinflammation","volume":"254","author":"Hamann","year":"2013","journal-title":"J Neuroimmunol"},{"key":"B62","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1189\/jlb.71.2.173","article-title":"Role of chemokines in the biology of natural killer cells","volume":"71","author":"Roberston","year":"2002","journal-title":"J Leukoc Biol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1084\/jem.193.6.713","article-title":"Absence of monocyte chemoattractive protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalitis","volume":"193","author":"Huang","year":"2001","journal-title":"J Exp Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jneuroim.2008.04.025","article-title":"Lymphoid chemokines in chronic neuroinflammation","volume":"198","author":"Aloisi","year":"2008","journal-title":"J Neuroimmunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3389\/fimmu.2017.01079","article-title":"CCL5-glutamate cross-talk in astrocyte-neuron communication in multiple sclerosis","volume":"8","author":"Pittaluga","year":"2017","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00401-006-0083-7","article-title":"Chemokine expression by astrocytes play a role in microglia\/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis","volume":"112","author":"Tanuma","year":"2006","journal-title":"Acta Neuropathol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.pediatrneurol.2013.07.019","article-title":"A role for the CXCR3\/CXCL10 axis in Rasmussen encephalitis","volume":"49","author":"Mirones","year":"2013","journal-title":"Pediatr Neurol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuropharm.2014.10.023","article-title":"IL-6 regulation of synaptic function in the CNS","volume":"96","author":"Gruol","year":"2015","journal-title":"Neuropharmacology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1194637","article-title":"Fate mapping analysis reveals that adult microglia derive from primitive macrophages","volume":"330","author":"Ginhoux","year":"2010","journal-title":"Science"},{"key":"B70","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/glia.22739","article-title":"Analysis of IL-6\/gp130 family receptor expression reveals that in contrast to astroglia, microglia lack the oncostatin M receptor and functional responses to oncostatin M","volume":"63","author":"Hsu","year":"2015","journal-title":"Glia"},{"key":"B71","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1152\/physrev.00024.2014","article-title":"Neuroglial transmission","volume":"95","author":"Gundersen","year":"2015","journal-title":"Physiol Rev"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2018.01.012","article-title":"The signaling role for chloride in the bidirectional communication between neurons and astrocytes","author":"Wilson","year":"2018","journal-title":"Neurosci Lett"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1515\/revneuro-20017-0092","article-title":"Gliotransmitters and cytokines in the control of blood-brain barrier permeability","author":"Osipova","year":"2018","journal-title":"Rev Neurosci"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1172\/JCI31720","article-title":"APC-derived cytokines and T cell polarization in autoimmune inflammation","volume":"117","author":"Gutcher","year":"2007","journal-title":"J Clin Invest"},{"key":"B75","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cellsig.2009.10.012","article-title":"GPCR signaling to the translation machinery","volume":"22","author":"Musnier","year":"2010","journal-title":"Cell Signal"},{"key":"B76","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jaut.2017.06.006","article-title":"Small molecules to the rescue: inhibition of cytokine signaling in immune-mediated diseases","volume":"85","author":"Gadina","year":"2017","journal-title":"J Autoimmun"},{"key":"B77","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/imr.12605","article-title":"Suppression of inflammation and acquired immunity by IL-37","volume":"281","author":"Cavalli","year":"2018","journal-title":"Immunol Rev"},{"key":"B78","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/ni.3772","article-title":"Limiting inflammation \u2013 the negative regulation of NF-\u03baB and the NLRP3 inflammasome","volume":"18","author":"Afonina","year":"2017","journal-title":"Nat Immunol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1742-2094-10-10","article-title":"BAFF\/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy","volume":"10","author":"Pranzatelli","year":"2013","journal-title":"J Neuroinflammation"},{"key":"B80","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/cei.12065","article-title":"Expression of CXCR3 and its ligands CXCL9, -10, -11 in pediatric OMS","volume":"172","author":"Pranzatelli","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jneuroim.2011.12.014","article-title":"Key role of CXCL13\/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS","volume":"243","author":"Pranzatelli","year":"2012","journal-title":"J Neuroimmunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1177\/1352458512473362","article-title":"CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions","volume":"19","author":"Alvarez","year":"2013","journal-title":"Mult Scler"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1212\/WNL.0b013e3181c5b457","article-title":"Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS","volume":"73","author":"Sellebjerg","year":"2009","journal-title":"Neurology"},{"key":"B84","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3389\/fimmu.2017.00531","article-title":"Elevated levels of proinflammatory cytokines in cerebrospinal fluid of multiple sclerosis patients","volume":"8","author":"Khaibullin","year":"2017","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1212\/NXI.0000000000000309","article-title":"B-cell populations discriminate between pediatric- and adult-onset multiple sclerosis","volume":"4","author":"Schwarz","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2015.10.002","article-title":"Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis","volume":"289","author":"Horellou","year":"2015","journal-title":"J Neuroimmunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1212\/NXI.0000000000000134","article-title":"Update on biomarkers in neuromyelitis optica","volume":"2","author":"Melamed","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult Scler"},{"key":"B89","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1017\/S0317167100015663","article-title":"Cerebrospinal fluid IL-21 levels in neuromyelitis optica and multiple sclerosis","volume":"39","author":"Wu","year":"2012","journal-title":"Can J Neurol Sci"},{"key":"B90","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jneuroim.2015.10.005","article-title":"The poor recovery of neuromyelitis optica spectrum disorder is associated with a lower level of CXCL12 in the human brain","volume":"289","author":"Kang","year":"2015","journal-title":"J Neuroinflammation"},{"key":"B91","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jneuroim.2006.03.020","article-title":"CSF cytokine and chemokine profiles in acute disseminated encephalomyelitis","volume":"175","author":"Ishizu","year":"2006","journal-title":"J Neuroimmunol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"260473","DOI":"10.1155\/2012\/260473","article-title":"IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barr\u00e9 syndrome","volume":"2012","author":"Li","year":"2012","journal-title":"Mediators Inflamm"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/j.jocn.2009.03.044","article-title":"Detection of MCP-1 and IL-8 in the serum and cerebrospinal fluid of a child with Miller Fisher syndrome","volume":"16","author":"Sato","year":"2009","journal-title":"J Clin Neurosci"},{"key":"B94","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jneuroim.2009.03.006","article-title":"Elevated B-cell activating factor BAFF, but not APRIL, correlated with CSF cerebellar antibodies in pediatric opsoclonus-myoclonus syndrome","volume":"210","author":"F\u00fchlhuber","year":"2009","journal-title":"J Neuroimmunol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1212\/NXI.0000000000000433","article-title":"Neuroimmunology of OMS and ANNA-1\/Anti-Hu paraneoplastic syndromes in a child with neuroblastoma","volume":"5","author":"Pranzatelli","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B96","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1001\/jamaneurol.2014.2956","article-title":"Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment response","volume":"72","author":"Leypoldt","year":"2015","journal-title":"JAMA Neurol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12974-016-0507-9","article-title":"Anti-N-methyl-D-aspartate receptor encephalitis: the clinical course in light of the chemokine and cytokine levels in cerebrospinal fluid","volume":"13","author":"Liba","year":"2016","journal-title":"J Neuroinflammation"},{"key":"B98","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0165-5728(03)00012-2","article-title":"CSF and serum immune parameters in Sydenham\u2019s chorea: evidence of an autoimmune disease","volume":"136","author":"Church","year":"2003","journal-title":"J Neuroimmunol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/ana.24494","article-title":"A destructive feedback loop mediated by CXCL10 in central nervous system inflammatory disease","volume":"78","author":"Roberts","year":"2015","journal-title":"Ann Neurol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/ana.24806","article-title":"Febrile infection-related epilepsy syndrome treated with anakinra","volume":"80","author":"Kenney-Jung","year":"2016","journal-title":"Ann Neurol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1111\/j.1528-1167.2008.01977.x","article-title":"A substantial number of Rasmussen syndrome patients have increased IgG, CD4+ T cells, TNF\u03b1, and Granzyme B in CSF","volume":"50","author":"Takahashi","year":"2009","journal-title":"Epilepsia"},{"key":"B102","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.braindev.2005.03.007","article-title":"Cerebrospinal fluid interleukin-6 levels in patients with West syndrome","volume":"28","author":"Tekgul","year":"2006","journal-title":"Brain Dev"},{"key":"B103","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.eplepsyres.2009.03.013","article-title":"Reduced levels of interleukin-1 receptor antagonists in the cerebrospinal fluid in patients with West syndrome","volume":"85","author":"Haginoya","year":"2009","journal-title":"Epilepsy Res"},{"key":"B104","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/glia.20639","article-title":"Astrocytes produce interferon-alpha and CXCL10, but not IL-6 or CXCL8, in Aicardi-Gouti\u00e8res syndrome","volume":"56","author":"Van Heteren","year":"2008","journal-title":"Glia"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/art.22451","article-title":"Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus","volume":"56","author":"Fragoso-Loyo","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B106","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1177\/0961203316629556","article-title":"IL-6, IL-8, IP-10, MCP-1 and G-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus","volume":"25","author":"Yoshio","year":"2016","journal-title":"Lupus"},{"key":"B107","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.clim.2015.01.010","article-title":"Distinguishing the cerebrospinal fluid cytokine profile in neuropsychiatric systemic lupus erythematosus from other autoimmune neurological diseases","volume":"157","author":"Ichinose","year":"2015","journal-title":"Clin Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.1212\/NXI.0000000000000316","article-title":"Characteristics and pharmacodynamics of severe neuroinflammation in a child with neurolupus","volume":"4","author":"Pranzatelli","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B109","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cyto.2008.10.007","article-title":"Interleukin-6 in neuro-Beh\u00e7et\u2019s disease: association with disease subsets and long-term outcome","volume":"44","author":"Akman-Demir","year":"2008","journal-title":"Cytokine"},{"key":"B110","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3109\/s10165-006-0507-1","article-title":"A pediatric patient with neuro-Beh\u00e7et\u2019s disease","volume":"16","author":"Hatachi","year":"2006","journal-title":"Mod Rheumatol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1046\/j.1365-2249.1997.4621483.x","article-title":"Intrathecal release of pro- and anti-inflammatory cytokine during stroke","volume":"110","author":"Tarkowski","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"B112","first-page":"1","article-title":"The level of chemokine CXCL5 in the cerebrospinal fluid is increased during the first 24 hours of ischaemic stroke and correlates with the size of early brain damage","volume":"65","author":"Zaremba","year":"2016","journal-title":"Folia Morphol (Warsz)"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1002\/art.40055","article-title":"CSF cytokines correlate with aseptic meningitis and blood brain barrier function in Neonatal-Onset Multisystem Inflammatory Disease (NOMID)","author":"Rodriguez-Smith","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1089\/neu.2007.0349","article-title":"Multiplex assessment of cytokine and chemokine levels in cerebrospinal fluid following severe pediatric traumatic brain injury: effects of moderate hypothermia","volume":"24","author":"Buttram","year":"2007","journal-title":"J Neurotrauma"},{"key":"B115","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/00130478-200107000-00013","article-title":"The Th1 versus Th2 cytokine profile in cerebrospinal fluid after severe traumatic brain injury in infants and children","volume":"2","author":"Amick","year":"2001","journal-title":"Pediatr Crit Care Med"},{"key":"B116","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12987-017-0083-0","article-title":"Chemokine and cytokine levels in the lumbar cerebrospinal fluid of preterm infants with post-hemorrhagic hydrocephalus","volume":"14","author":"Habiyaremyew","year":"2017","journal-title":"Fluids Barriers CNS"},{"key":"B117","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1212\/01.wnl.0000326589.57128.c3","article-title":"Distinct CSF cytokine\/chemokine profiles in atopic myelitis and other causes of myelitis","volume":"71","author":"Tanaka","year":"2008","journal-title":"Neurology"},{"key":"B118","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jns.2007.10.009","article-title":"Sj\u00f6gren\u2019s syndrome-associated meningoencephalomyelitis: cerebrospinal fluid cytokine levels and therapeutic utility of tacrolimus","volume":"267","author":"Hoshina","year":"2008","journal-title":"J Neurol Sci"},{"key":"B119","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00011-015-0896-8","article-title":"Cytokines and matrix metalloproteinases in the cerebrospinal fluid of patients with acute transverse myelitis: an outcome analysis","volume":"65","author":"Dixit","year":"2016","journal-title":"Inflamm Res"},{"key":"B120","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12974-017-0863","article-title":"Early strong intrathecal inflammation in cerebellar type multiple system atrophy by cerebrospinal fluid cytokine\/chemokine profiles: a case control study","volume":"14","author":"Yamasaki","year":"2017","journal-title":"J Neuroinflammation"},{"key":"B121","doi-asserted-by":"publisher","first-page":"24579","DOI":"10.1038\/srep24579","article-title":"Cerebral spinal fluid levels of cytokines are elevated in patients with metachromatic leukodystrophy","volume":"15","author":"Thibert","year":"2016","journal-title":"Sci Rep"},{"key":"B122","doi-asserted-by":"publisher","first-page":"e32218","DOI":"10.1371\/journal.pone.0032218","article-title":"Elevated cerebral spinal fluid cytokine levels in boys with cerebral adrenoleukodystrophy correlates with MRI severity","volume":"7","author":"Lund","year":"2012","journal-title":"PLoS One"},{"key":"B123","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1177\/1352458509355068","article-title":"Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid","volume":"16","author":"Mellerg\u00e5rd","year":"2010","journal-title":"Mult Scler"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-017-3227-8","article-title":"Chemokines CXCL10, CXCL11, and CXCL13 in acute disseminated encephalomyelitis, non-polio enterovirus aseptic meningitis, and neuroborreliosis: CXCL10 as initial discriminator in diagnostic algorithm?","author":"Maric","year":"2017","journal-title":"Neurol Sci"},{"key":"B125","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1212\/WNL.0b013e3182872694","article-title":"Elevation of proinflammatory cytokines in patients with Aicardi-Gouti\u00e8res syndrome","volume":"80","author":"Takanohashi","year":"2013","journal-title":"Neurology"},{"key":"B126","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ymgme.2014.11.015","article-title":"Biomarkers of central nervous system inflammation in infantile and juvenile gangliosidoses","volume":"1114","author":"Utz","year":"2015","journal-title":"Mol Genet Metab"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/jnr.23804","article-title":"Neuroimmune mechanisms in Krabbe\u2019s disease","volume":"94","author":"Potter","year":"2016","journal-title":"J Neurosci Res"},{"key":"B128","doi-asserted-by":"publisher","first-page":"e11986","DOI":"10.1371\/journal.pone.0011986","article-title":"The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS)","volume":"5","author":"Brettschneider","year":"2010","journal-title":"PLoS One"},{"key":"B129","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/1352458513491166","article-title":"Interleukin-12p40 in the spinal fluid as a biomarker for clinically isolated syndrome","volume":"20","author":"Orbach","year":"2014","journal-title":"Mult Scler"},{"key":"B130","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jns.2016.07.052","article-title":"Interleukin 17b alone is not a discriminant biomarker ion early demyelinating spectrum disorders","volume":"368","author":"Lebrun","year":"2016","journal-title":"J Neurol Sci"},{"key":"B131","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00415-002-0699-z","article-title":"Multiple sclerosis and optic neuritis: CCR5 and CXCR3 expressing T cells are augmented in blood and cerebrospinal fluid","volume":"249","author":"Teleshova","year":"2002","journal-title":"J Neurol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1177\/117727190700200028","article-title":"Increased intrathecal chemokine receptor CCR2 expression in multiple sclerosis","volume":"2","author":"Nakajima","year":"2007","journal-title":"Biomark Insights"},{"key":"B133","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.4049\/jimmunol.1202026","article-title":"CCR2(+) CCR5(+) T cells produce matrix metalloproteinase-9 and osteopontin in the pathogenesis of multiple sclerosis","volume":"189","author":"Sato","year":"2012","journal-title":"J Immunol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"e3222","DOI":"10.1097\/MD.0000000000003222","article-title":"Clinical value of assessing cytokine levels for the differential diagnosis of bacterial meningitis in a pediatric population","volume":"95","author":"Ye","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"B135","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cyto.2010.03.001","article-title":"IL-17 is elevated in cerebrospinal fluids in bacterial meningitis in children","volume":"51","author":"Asano","year":"2010","journal-title":"Cytokine"},{"key":"B136","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1177\/08830738020170101501","article-title":"Interleukin-1beta, tumor necrosis factor-alpha, and nitrite levels in febrile seizures","volume":"17","author":"Haspolat","year":"2002","journal-title":"J Child Neurol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S0165-5728(01)00451-9","article-title":"Recruitment of dendritic cells to the cerebrospinal fluid in bacterial neuroinfections","volume":"122","author":"Pashenkov","year":"2002","journal-title":"J Neuroimmunol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1742-2094-8-36","article-title":"Indications of Th1 and Th17 responses in cerebrospinal fluid from patients with Lyme neuroborreliosis: a large retrospective study","volume":"8","author":"Henningsson","year":"2011","journal-title":"J Neuroinflammation"},{"key":"B139","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1212\/01.wnl.0000171349.06645.79","article-title":"The chemokine CXCL13 (BLC): a putative diagnostic marker for neuroborreliosis","volume":"65","author":"Rupprecht","year":"2005","journal-title":"Neurology"},{"key":"B140","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0165-5728(02)00255-2","article-title":"Increased expression of the Th1-inducing cytokines interleukin-12 and interleukin-18 in cerebrospinal fluid but not sera from patients with Lyme neuroborreliosis","volume":"131","author":"Grusell","year":"2002","journal-title":"J Neuroimmunol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1128\/JCM.00084-11","article-title":"Discriminating Lyme neuroborreliosis from other neuroinflammatory diseases by levels of CXCL13 in cerebrospinal fluid","volume":"49","author":"Van Burgel","year":"2011","journal-title":"J Clin Microbiol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1600-0404.2010.01477.x","article-title":"CXCL13 chemokine in pediatric and adult neuroborreliosis","volume":"124","author":"Wutte","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"B143","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/2045-8118-10-30","article-title":"Th1 and Th17 but no Th2-related cytokine spectrum in the cerebrospinal fluid of children with Borrelia-related facial nerve palsy","volume":"10","author":"Liba","year":"2013","journal-title":"Fluids Barriers CNS"},{"key":"B144","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12987-015-0008-8","article-title":"The chemokine CXCL13 is elevated in the cerebrospinal fluid of patients with neurosyphilis","volume":"12","author":"Dersch","year":"2015","journal-title":"Fluids Barriers CNS"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1128\/JCM.02917-14","article-title":"Has CXCL13 an added value in diagnosis of neurosyphilis","volume":"53","author":"Mothapo","year":"2015","journal-title":"J Clin Microbiol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.pediatrneurol.2005.03.003","article-title":"Cytokines involved in CNS manifestations caused by Mycoplasma pneumoniae","volume":"33","author":"Narita","year":"2005","journal-title":"Pediatr Neurol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12974-017-0898-2","article-title":"The increased concentration of macrophage migration inhibitory factor in serum and cerebrospinal fluid of patients with tick-borne encephalitis","volume":"14","author":"Grygorczuk","year":"2017","journal-title":"J Neuroinflammation"},{"key":"B148","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1097\/INF.0000000000001210","article-title":"Biomarkers in cerebrospinal fluid of children with tick-borne encephalitis: association with long-term outcome","volume":"35","author":"Fowler","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"B149","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.neulet.2010.02.017","article-title":"Cytokines and chemokines in viral encephalitis: a clinicoradiological correlation","volume":"473","author":"Kalita","year":"2010","journal-title":"Neurosci Lett"},{"key":"B150","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1177\/0883073816653780","article-title":"Cytokine and chemokine expression in CSF may differentiate viral and autoimmune NMDAR encephalitis in children","volume":"31","author":"Ygberg","year":"2016","journal-title":"J Child Neurol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-017-0907-5","article-title":"CXCL11 production in cerebrospinal fluid distinguishes herpes simplex meningitis from herpes simplex encephalitis","volume":"14","author":"Lind","year":"2017","journal-title":"J Neuroinflammation"},{"key":"B152","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/1348-0421.12227","article-title":"Cerebrospinal fluid Th1\/Th2 cytokine profiles in children with enterovirus 71-associated meningoencephalitis","volume":"59","author":"Li","year":"2015","journal-title":"Microbiol Immunol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1442-200X.2010.03215.x","article-title":"Enhanced expression of cytokines\/chemokines in cerebrospinal fluids in mumps meningitis in children","volume":"53","author":"Asano","year":"2011","journal-title":"Pediatr Int"},{"key":"B154","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s13365-016-0437-4","article-title":"Biomarkers of chemotaxis and inflammation in cerebrospinal fluid and serum in individuals with HIV-1 subtype C versus B","volume":"22","author":"De Almeida","year":"2016","journal-title":"J Neurovirol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1749-6632.1993.tb26259.x","article-title":"Central nervous system pathology in pediatric AIDS","volume":"693","author":"Dickson","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"B156","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.cyto.2005.08.004","article-title":"Elevated interleukin-12 and CXCL10 in subacute sclerosing panencephalitis","volume":"32","author":"Saruhan-Direskeneli","year":"2005","journal-title":"Cytokine"},{"key":"B157","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.braindev.2009.04.018","article-title":"Serum and cerebrospinal fluid cytokine concentrations in subacute sclerosing panencephalitis","volume":"32","author":"Aydin","year":"2010","journal-title":"Brain Dev"},{"key":"B158","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cyto.2005.11.009","article-title":"Analysis of serum and cerebrospinal fluid cytokine levels in subacute sclerosing panencephalitis in Papua New Guinea","volume":"33","author":"Ichiyama","year":"2006","journal-title":"Cytokine"},{"key":"B159","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/infdis\/175.3.689","article-title":"Increased levels of interleukin-1beta and soluble intercellular adhesion molecule-1 in cerebrospinal fluid of patients with subacute sclerosing panencephalitis","volume":"175","author":"Mehta","year":"1997","journal-title":"J Infect Dis"},{"key":"B160","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/WCO.0b013e32833950dd","article-title":"Mechanisms of injury in bacterial meningitis","volume":"23","author":"Gerber","year":"2010","journal-title":"Curr Opin Neurol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coviro.2014.12.009","article-title":"Viral diseases of the central nervous system","volume":"11","author":"Swanson","year":"2015","journal-title":"Curr Opin Virol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1128\/CVI.00353-13","article-title":"Diagnostic value of cytokines and chemokines in Lyme neuroborreliosis","volume":"20","author":"Cerar","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/pr.2016.117","article-title":"Cerebrospinal fluid cytokines in the diagnosis of bacterial meningitis in infants","volume":"80","author":"Srinivasan","year":"2016","journal-title":"Pediatr Res"},{"key":"B164","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pediatrneurol.2013.08.016","article-title":"Cerebrospinal fluid TNF-\u03b1, IL-6, and IL-8 in children with bacterial meningitis","volume":"50","author":"Prasad","year":"2014","journal-title":"Pediatr Neurol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/1471-2334-13-326","article-title":"Cerebrospinal-fluid cytokine and chemokine profile in patients with pneumococcal and meningococcal meningitis","volume":"13","author":"Coutinho","year":"2013","journal-title":"BMC Infect Dis"},{"key":"B166","doi-asserted-by":"publisher","first-page":"312476","DOI":"10.1155\/2013\/312476","article-title":"The causative pathogen determines the inflammatory profile in cerebrospinal fluid and outcome in patients with bacterial meningitis","volume":"2013","author":"Grandgirard","year":"2013","journal-title":"Mediators Inflamm"},{"key":"B167","doi-asserted-by":"publisher","first-page":"218","DOI":"10.5114\/ceji.2017.69366","article-title":"Dengue virus and Japanese encephalitis virus infection of the central nervous system share similar profiles of cytokine accumulation in cerebrospinal fluid","volume":"42","author":"Li","year":"2017","journal-title":"Cent Eur J Immunol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12879-015-12035-4","article-title":"Divergent cerebrospinal fluid cytokine network induced by non-viral and different viral infections on the central nervous system","volume":"15","author":"Bastos","year":"2015","journal-title":"BMC Infect Dis"},{"key":"B169","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.cyto.2011.07.016","article-title":"Increased levels of cytokines and high-mobility group box 1 are associated with the development of severe pneumonia, but not acute encephalopathy, in 2009 H1N1 influenza-infected children","volume":"56","author":"Ito","year":"2011","journal-title":"Cytokine"},{"key":"B170","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/imr.12091","article-title":"Virus infection, antiviral immunity, and autoimmunity","volume":"255","author":"Getts","year":"2013","journal-title":"Immunol Rev"},{"key":"B171","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3390\/v2020574","article-title":"CCR5: from natural resistance to a new anti-HIV strategy","volume":"2","author":"Lopalco","year":"2010","journal-title":"Viruses"},{"key":"B172","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1111\/j.1476-5381.2011.01551.x","article-title":"Pharmacological modulation of chemokine receptor function","volume":"165","author":"Scholten","year":"2011","journal-title":"Br J Pharmacol"},{"key":"B173","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1089\/088282401753266756","article-title":"Virus-induced autoimmunity: potential role of viruses in initiation, perpetuation, and progression of T-cell-mediated autoimmune disease","volume":"14","author":"Olson","year":"2001","journal-title":"Viral Immunol"},{"key":"B174","doi-asserted-by":"publisher","first-page":"1","DOI":"10.10007\/s11908-017-0556-y","article-title":"NMDAR encephalitis following herpes simplex virus encephalitis","volume":"19","author":"Galli","year":"2017","journal-title":"Curr Infect Dis Rep"},{"key":"B175","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.autrev.2012.12.005","article-title":"Infectome: a platform to trace infectious triggers of autoimmunity","volume":"12","author":"Bogdanos","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B176","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.spen.2017.08.009","article-title":"Introduction [to special issue on immune mechanisms in neurological disorders]","volume":"24","author":"Pranzatelli","year":"2017","journal-title":"Semin Pediatr Neurol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"14746","DOI":"10.1038\/srep14746","article-title":"A strategy to discover decoy chemokine ligands with an anti-inflammatory activity","volume":"5","author":"Abboud","year":"2015","journal-title":"Sci Rep"},{"key":"B178","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.cyto.2015.02.011","article-title":"Targeting chemokines: pathogens do it, why can\u2019t we?","volume":"74","author":"Proudfoot","year":"2015","journal-title":"Cytokine"},{"key":"B179","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrrheum.2015.157","article-title":"Successes and failures of chemokine-pathway targeting in rheumatoid arthritis","volume":"12","author":"Szekanecz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/HAB-160305","article-title":"Antibody mimicry, receptors and clinical applications","volume":"25","author":"Horenstein","year":"2017","journal-title":"Hum Antibodies"},{"key":"B181","unstructured":"General Policies for Monoclonal Antibodies. INN Working Document 09.2512009"},{"key":"B182","volume-title":"Revised Monoclonal Antibody (mAb) Nomenclature Scheme. INN Working Doc. 17.416","year":"2017"},{"key":"B183","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00253-010-2590-7","article-title":"Recombinant immunotherapeutics: current state and perspectives regarding the feasibility and market","volume":"87","author":"Huang","year":"2010","journal-title":"Appl Microbiol Biotechnol"},{"key":"B184","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s40265-017-0724-2","article-title":"Sarilumab: first global approval","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.2174\/0929867324666170712160621","article-title":"Immunotherapeutic interleukin-6 or interleukin-6 receptor blockade in cancer: challenges and opportunities","author":"Kampan","year":"2017","journal-title":"Curr Med Chem"},{"key":"B186","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1002\/cbic.201600303","article-title":"Minimalist antibodies and mimetics: an update and recent applications","volume":"17","author":"Bruce","year":"2016","journal-title":"Chembiochem"},{"key":"B187","doi-asserted-by":"publisher","first-page":"25173","DOI":"10.1074\/jbc.M113.467969","article-title":"Neutralizing nanobodies targeting diverse chemokines effectively inhibit chemokine function","volume":"288","author":"Blanchelot","year":"2013","journal-title":"J Biol Chem"},{"key":"B188","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1189\/jlb.3MA0117-025R","article-title":"Can we design a better anti-cytokine therapy?","volume":"102","author":"Drutskaya","year":"2017","journal-title":"J Leukoc Biol"},{"key":"B189","doi-asserted-by":"publisher","first-page":"e018278","DOI":"10.1371\/journal.pone.0184278","article-title":"A fully humanized IgG-like bispecific antibody for effective dual targeting of CXCR3 and CCR6","volume":"12","author":"Robert","year":"2017","journal-title":"PLoS One"},{"key":"B190","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.cbpa.2009.04.627","article-title":"Engineered protein scaffolds as next-generation antibody therapeutics","volume":"13","author":"Gebauer","year":"2009","journal-title":"Curr Opin Chem Biol"},{"key":"B191","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev-anchem-061516-045205","article-title":"Beyond antibodies as binding partners: the role of antibody mimetics in bioanalysis","volume":"10","author":"Yu","year":"2017","journal-title":"Annu Rev Anal Chem (Palo Alto Calif)"},{"key":"B192","doi-asserted-by":"publisher","first-page":"66","DOI":"10.5966\/sctm.2014-0145","article-title":"Concise review: engineering the fusion of cytokines for the modulation of immune cellular responses in cancer and autoimmune disorders","volume":"4","author":"Ng","year":"2015","journal-title":"Stem Cells Transl Med"},{"key":"B193","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s10529-014-1746-4","article-title":"CXCL10\/XCL1 fusokine elicits in vitro and in vivo chemotaxis","volume":"37","author":"Sanchez-Lugo","year":"2015","journal-title":"Biotechnol Lett"},{"key":"B194","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.4049\/jimmunol.1003699","article-title":"GM-CSF-based fusion cytokines as ligands for immune modulation","volume":"186","author":"Williams","year":"2011","journal-title":"J Immunol"},{"key":"B195","doi-asserted-by":"publisher","first-page":"248","DOI":"10.2174\/187152612800564392","article-title":"Reprogramming of B cells into regulatory cells with engineered fusokines","volume":"12","author":"Deng","year":"2012","journal-title":"Infect Disord Drug Targets"},{"key":"B196","doi-asserted-by":"publisher","first-page":"5683","DOI":"10.1158\/0008-5472.CAN-16-0386","article-title":"Stimulation of natural killer cell-mediated tumor immunity by an IL-15\/TGF-\u03b2 neutralizing fusion protein","volume":"76","author":"Ng","year":"2016","journal-title":"Cancer Res"},{"key":"B197","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12028-017-0378-7","article-title":"Cerebrospinal fluid NLRP3 is increased after severe traumatic brain injury in infants and children","volume":"27","author":"Wallisch","year":"2017","journal-title":"Neurocrit Care"},{"key":"B198","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fncel.2017.00063","article-title":"NLRP3 inflammation in neurological diseases, from functions to therapies","volume":"11","author":"Song","year":"2017","journal-title":"Front Cell Neurosci"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211555","article-title":"Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematous, psoriasis, Crohn\u2019s disease and ulcerative colitis?","author":"Baker","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B200","doi-asserted-by":"publisher","first-page":"R34","DOI":"10.1186\/ar3266","article-title":"Canakinumab (ACZ885, a fully human IgG1 anti-IL-1\u03b2 mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)","volume":"13","author":"Kuemmerle-Deschner","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B201","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1136\/annrheumdis-2013-204877","article-title":"A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease","volume":"74","author":"Sibley","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B202","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N Engl J Med"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001840","article-title":"Safety and efficacy of reslizumab for children and adolescents with eosinophilic esophagitis treated over nine years","author":"Markowitz","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B204","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1158\/1078-0432.CCR-15-0134","article-title":"Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (anti-IL6 monoclonal antibody) in patients with multicentric Castleman diseases","volume":"21","author":"Casper","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B205","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.2147\/DDDT.S86438","article-title":"Siltuximab (CNTO 328): a promising option for human malignancies","volume":"9","author":"Chen","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"B206","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/art.39700","article-title":"The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis","volume":"68","author":"Mease","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B207","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","article-title":"Repeated subcutaneous injections of IL12\/23 p40 neutralizing antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomized, dose-ranging study","volume":"7","author":"Segal","year":"2008","journal-title":"Lancet Neurol"},{"key":"B208","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/jid.2011.304","article-title":"A phase III, randomized, controlled trial of the fully human IL-12\/23 mAb briakinumab in moderate-to-severe psoriasis","volume":"132","author":"Gordon","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B209","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patiuents with untrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomized, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Resp Med"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2451","article-title":"A first-in-human phase 1 study of subcutaneous outpatient recombinant human (rhIL-15) in adults with advanced solid tumors","author":"Miller","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B211","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1080\/21645515.2017.1356498","article-title":"Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis","volume":"13","author":"Jeon","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170429","article-title":"Efficacy and safety of Ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-PI)","author":"Van der Heijde","year":"2017","journal-title":"J Rheumatol"},{"key":"B213","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/art.39083","article-title":"Efficacy and safety of anti-interleukin-20 monoclonal antibody in patients with rheumatoid arthritis: a randomized phase IIa trial","volume":"67","author":"\u0160enolt","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an anti-IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments \u2013 a randomized, double-blind, phase 2a trial","author":"Guttman-Yassky","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16236","article-title":"Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study","author":"Nemoto","year":"2017","journal-title":"Br J Dermatol"},{"key":"B216","doi-asserted-by":"publisher","first-page":"e1257453","DOI":"10.1080\/2162402X.2016.1257453","article-title":"Novel TGF-\u03b2 inhibitors ready for prime time in onco-immunology","volume":"7","author":"De Gramont","year":"2016","journal-title":"Oncoimmunology"},{"key":"B217","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1136\/annrheumdis-2016-210246","article-title":"Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomized trial","volume":"76","author":"Atsumi","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B218","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1212\/WNL.0000000000004644","article-title":"Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series","volume":"89","author":"Gelfand","year":"2017","journal-title":"Neurology"},{"key":"B219","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/19420862.2015.1093266","article-title":"Discovery and characterization of COVA322, a clinical-stage bispecific TNF\/IL-17A inhibitor for the treatment of inflammatory diseases","volume":"8","author":"Silacci","year":"2016","journal-title":"MAbs"},{"key":"B220","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1212\/NXI.0000000000000117","article-title":"Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis","volume":"2","author":"Constantinesacu","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B221","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B222","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2147\/DDDT.S67264","article-title":"Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF\/APRIL targeting agents","volume":"9","author":"Lenert","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"B223","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1136\/annrheumdis-2013-205144","article-title":"A phase 2, randomized, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study","volume":"74","author":"Furie","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B224","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B225","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A phasae II study of the efficacy and safety of rontalizumab (rhuMAb interferon-\u03b1) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B226","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to sever systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B227","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1002\/art.34330","article-title":"A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis","volume":"64","author":"Yellen","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B228","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/archneurol.2012.595","article-title":"Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens","volume":"69","author":"Orange","year":"2012","journal-title":"Arch Neurol"},{"key":"B229","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1136\/gutjnl-2012-303424","article-title":"Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomized study","volume":"63","author":"Mayer","year":"2014","journal-title":"Gut"},{"key":"B230","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.tips.2005.11.001","article-title":"Chemokine blockers \u2013 therapeutics in the making","volume":"27","author":"Wells","year":"2006","journal-title":"Trends Pharmacol Sci"},{"key":"B231","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/1759720X17690474","article-title":"Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness","volume":"9","author":"Guerreiro Castro","year":"2017","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B232","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-14-2291","article-title":"Interleukin-6 as a therapeutic target","volume":"21","author":"Rossi","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B233","first-page":"52","article-title":"Anti-interferon-gamma antibodies in the treatment of autoimmune diseases","volume":"5","author":"Skurkovich","year":"2003","journal-title":"Curr Opin Mol Ther"},{"key":"B234","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1002\/art.21975","article-title":"A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis","volume":"54","author":"Haringman","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B235","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jns.2017.01.023","article-title":"TNF-alpha inhibitor associated myelopathies: a neurological complication in patients with rheumatological disorders","volume":"373","author":"Barreras","year":"2017","journal-title":"J Neurol Sci"},{"key":"B236","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor \u03b1 therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"B237","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.bpg.2008.12.005","article-title":"Serum sickness, encephalitis and other complications of anti-cytokine therapy","volume":"23","author":"Vermeire","year":"2009","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"B238","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1042\/CS20160415","article-title":"The innate immune system in human systemic lupus","volume":"131","author":"Weidenbusch","year":"2017","journal-title":"Clin Sci"},{"key":"B239","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1177\/0961203316652495","article-title":"Interferon-targeted therapy in systemic lupus erythematosus: is this an alternative to targeting B and T cells?","volume":"25","author":"Kalunian","year":"2016","journal-title":"Lupus"},{"key":"B240","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study","volume":"53","year":"1999","journal-title":"Neurology"},{"key":"B241","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00401-015-1402-7","article-title":"The role of IL-17 in CNS diseases","volume":"129","author":"Waisman","year":"2015","journal-title":"Acta Neuropathol"},{"key":"B242","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/epi.13387","article-title":"Anti-tumor necrosis factor alpha therapy (adalimumab) in Rasmussen\u2019s encephalitis: an open pilot study","volume":"57","author":"Lagarde","year":"2016","journal-title":"Epilepsia"},{"key":"B243","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1212\/01.WNL.0000099074.04539.E0","article-title":"Experience with immunomodulatory treatments in Rasmussen\u2019s encephalitis","volume":"61","author":"Granata","year":"2003","journal-title":"Neurology"},{"key":"B244","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.pediatrneurol.2017.05.015","article-title":"First pediatric patient with neuromyelitis optica and Sjogren\u2019s syndrome successfully treated with tocilizumab","volume":"73","author":"Marino","year":"2017","journal-title":"Pediatr Neurol"},{"key":"B245","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"key":"B246","first-page":"361","article-title":"Limbic encephalitis associated with relapsing polychondritis responded to infliximab and maintained its condition without recurrence after discontinuation: a case report and review of the literature","volume":"76","author":"Kondo","year":"2014","journal-title":"Nagoya J Med Sci"},{"key":"B247","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00415-017-8444-9","article-title":"Long-term outcomes of refractory neurosarcoidosis treated with infliximab","volume":"264","author":"Cohen Aubart","year":"2017","journal-title":"J Neurol"},{"key":"B248","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.cyto.2012.02.016","article-title":"Interleukin-1 receptor antagonist reverses stroke-associated peripheral immune suppression","volume":"58","author":"Smith","year":"2012","journal-title":"Cytokine"},{"key":"B249","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/acn3.181","article-title":"Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis","volume":"2","author":"Lin","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"key":"B250","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/archneurol.2011.581","article-title":"Daclizumab use in patients with pediatric multiple sclerosis","volume":"69","author":"Gorman","year":"2012","journal-title":"Arch Neurol"},{"key":"B251","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"B252","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"B253","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1080\/21645515.2017.1316909","article-title":"Tocilizumab (Actemra)","volume":"13","author":"Sheppard","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"B254","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s13311-016-0442-6","article-title":"Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study","volume":"13","author":"Lee","year":"2016","journal-title":"Neurotherapeutics"},{"key":"B255","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"B256","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder","volume":"72","author":"Ringelstein","year":"2015","journal-title":"JAMA Neurol"},{"key":"B257","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3109\/14397595.2015.1074648","article-title":"Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: results from a randomized phase II trial","volume":"26","author":"Takeuchi","year":"2016","journal-title":"Mod Rheumatol"},{"key":"B258","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1358\/dot.2017.53.5.2613690","article-title":"Brodalumab: the first anti-IL-17 receptor agent for psoriasis","volume":"53","author":"Puig","year":"2017","journal-title":"Drugs Today (Barc)"},{"key":"B259","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10787-015-0229-0","article-title":"Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs","volume":"23","author":"Jinesh","year":"2015","journal-title":"Inflammopharmacology"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1002\/art.40420","article-title":"Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptors \u03b1 monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis","author":"Burmester","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B261","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.2174\/156802610791561237","article-title":"CCR1 antagonists: what have we learned from clinical trials","volume":"10","author":"Gladue","year":"2010","journal-title":"Curr Top Med Chem"},{"key":"B262","doi-asserted-by":"publisher","first-page":"e1011524","DOI":"10.1080\/2162402X.2015.1011524","article-title":"Depletion of regulatory T cells by targeting CC chemokines receptor type 4 with mogamulizumab","volume":"4","author":"Ni","year":"2015","journal-title":"Oncoimmunology"},{"key":"B263","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.1128\/AAC.00086-10","article-title":"Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults","volume":"54","author":"Jacobson","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"B264","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrneurol.2015.248","article-title":"CCR5 blockade for neuroinflammatory diseases \u2013 beyond control of HIV","volume":"12","author":"Martin-Blondel","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"B265","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/apt.13398","article-title":"Randomized clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn\u2019s disease","volume":"42","author":"Feagan","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"B266","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/17474086.2016.1208082","article-title":"Plexifor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma","volume":"9","author":"Jantunen","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"B267","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3389\/fimmu.2016.00183","article-title":"Modulation of chemokine responses: synergy and cooperativity","volume":"7","author":"Proudfoot","year":"2016","journal-title":"Front Immunol"},{"key":"B268","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ejphar.2015.05.018","article-title":"Targeting chemokine receptors in disease \u2013 a case study of CCR4","volume":"763","author":"Solari","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"B269","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1080\/21646821.2017.1355181","article-title":"Febrile infection-related epilepsy syndrome (FIRES): a literature review and case study","volume":"57","author":"Fox","year":"2017","journal-title":"Neurodiagn J"},{"key":"B270","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1056\/NEJMoa0807865","article-title":"An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist","volume":"360","author":"Aksentijevich","year":"2009","journal-title":"N Engl J Med"},{"key":"B271","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.pharmthera.2011.09.005","article-title":"Monoclonal antibodies for the treatment of asthma","volume":"231","author":"Catlet","year":"2011","journal-title":"Pharmacol Ther"},{"key":"B272","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00262-015-1670-z","article-title":"Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia","volume":"64","author":"Cuesta-Mateos","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B273","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.4049\/jimmunol.0713169","article-title":"Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response","volume":"182","author":"Liston","year":"2009","journal-title":"J Immunol"},{"key":"B274","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12865-015-0068-1","article-title":"CXCL13 antibody for the treatment of autoimmune disorders","volume":"16","author":"Klimatcheva","year":"2015","journal-title":"BMC Immunol"},{"key":"B275","doi-asserted-by":"publisher","first-page":"7581","DOI":"10.4049\/jimmunol.181.11.7581","article-title":"A new approach to the blocking of alloreactive T cell-mediated graft-vs-host disease by in vivo administration of anti-CXCR3 neutralizing antibody","volume":"181","author":"He","year":"2009","journal-title":"J Immunol"},{"key":"B276","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1002\/ijc.28893","article-title":"Immunotherapy of B-cell non-Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model","volume":"135","author":"Panjideh","year":"2014","journal-title":"Int J Cancer"},{"key":"B277","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3727\/096368916X693563","article-title":"A novel CXCR4 antagonist CX549 induces neuroprotection in stroke brain","volume":"26","author":"Wu","year":"2017","journal-title":"Cell Transplant"},{"key":"B278","doi-asserted-by":"publisher","first-page":"12641","DOI":"10.1074\/jbc.M116.721050","article-title":"I-bodies, human single domain antibodies that antagonize chemokine receptor CXCR4","volume":"291","author":"Griffiths","year":"2016","journal-title":"J Biol Chem"},{"key":"B279","doi-asserted-by":"publisher","first-page":"77S","DOI":"10.2967\/jnumed.116.186874","article-title":"CXCR4 ligands: the next big hit?","volume":"58","author":"Walenkamp","year":"2017","journal-title":"J Nucl Med"},{"key":"B280","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0545-8","article-title":"Clinical and histopathological encephalomyelitis by AAV vectors expressing a soluble interleukin-23 receptor","author":"Miralles","year":"2017","journal-title":"Neurotherapeutics"},{"key":"B281","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.4049\/jimmunol.0803495","article-title":"Selective inhibition of CCR2 expressing lymphomyeloid cells in experimental autoimmune encephalomyelitis by a GMCSF-MCP1 fusokine","volume":"5","author":"Rafei","year":"2009","journal-title":"J Immunol"},{"key":"B282","doi-asserted-by":"publisher","first-page":"e27621","DOI":"10.1371\/journal.pone.0027621","article-title":"A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death","volume":"6","author":"Fischer","year":"2011","journal-title":"PLoS One"},{"key":"B283","doi-asserted-by":"publisher","first-page":"eaaf8608","DOI":"10.1126\/scisignal.aaf8608","article-title":"Targeting TNFR2 with antagonist antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs","volume":"10","author":"Torrey","year":"2017","journal-title":"Sci Signal"},{"key":"B284","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/glia.23154","article-title":"Type I interferon pathway in CNS homeostasis and neurological disorders","volume":"65","author":"Blank","year":"2017","journal-title":"Glia"},{"key":"B285","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2217\/nmt.15.52","article-title":"IFN-\u03b3 for Friedreich ataxia: present evidence","volume":"5","author":"Wells","year":"2015","journal-title":"Neurodegener Dis Manag"},{"key":"B286","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1212\/WNL.37.7.1097","article-title":"Treatment of multiple sclerosis with \u03b3 interferon: exacerbations associated with activation of the immune system","volume":"37","author":"Panitch","year":"1987","journal-title":"Neurology"},{"key":"B287","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jneuroim.2016.09.001","article-title":"New feasible treatment for refractory autoimmune encephalitis low-dose interleukin-2","volume":"299","author":"Lim","year":"2016","journal-title":"J Neuroimmunol"},{"key":"B288","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ana.24846","article-title":"Cytokine therapy-mediated neuroprotection in a Friedreich\u2019s ataxia mouse model","volume":"81","author":"Kemp","year":"2017","journal-title":"Ann Neurol"},{"key":"B289","doi-asserted-by":"publisher","first-page":"12472","DOI":"10.18632\/oncotarget.2998","article-title":"Classification of current anticancer immunotherapies","volume":"5","author":"Galluzzi","year":"2014","journal-title":"Oncotarget"},{"key":"B290","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.cytogfr.2011.11.005","article-title":"Probing cytokines, chemokines and matrix metalloproteinases towards better immunotherapies of multiple sclerosis","volume":"22","author":"Opdenakker","year":"2011","journal-title":"Cytokine Growth Factor Rev"},{"key":"B291","first-page":"31","article-title":"Consider the chemokines: a review of the interplay between chemokines and T cell subset function","volume":"24","author":"Strazza","year":"2017","journal-title":"Discov Med"},{"key":"B292","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1093\/brain\/awh176","article-title":"Development of biomarkers in multiple sclerosis","volume":"127","author":"Bielekova","year":"2004","journal-title":"Brain"},{"key":"B293","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.coi.2015.02.008","article-title":"The IL-6\/gp130\/STAT3 signaling axis: recent advances towards specific inhibition","volume":"34","author":"Garbers","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"B294","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/NIB-150101","article-title":"Targeting CXCL13 during neuroinflammation","volume":"6","author":"Huber","year":"2015","journal-title":"Adv Neuroimmune Biol"},{"key":"B295","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12974-016-0536-4","article-title":"CXCR3 signaling in glial cells ameliorates experimental encephalomyelitis by restraining the generation of a pro-Th17 cytokine milieu and reducing CNS-infiltrating Th17\u2009cells","volume":"13","author":"Chung","year":"2016","journal-title":"J Neuroinflammation"},{"key":"B296","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1044-5323(02)00125-2","article-title":"The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental encephalomyelitis (EAE)","volume":"15","author":"Mahad","year":"2003","journal-title":"Semin Immunol"},{"key":"B297","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1177\/1740774515597701","article-title":"The ethics and regulatory landscape of including vulnerable populations in pragmatic clinical trials","volume":"12","author":"Welch","year":"2015","journal-title":"Clin Trials"},{"key":"B298","doi-asserted-by":"publisher","first-page":"e20170195","DOI":"10.1542\/peds.2017-0195","article-title":"Methodological and ethical issues in pediatric medication safety research","volume":"149","author":"Carpenter","year":"2017","journal-title":"Pediatrics"},{"key":"B299","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nm.4016","article-title":"In vivo imaging of inflammasome activation reveals a subcapsular macrophage burst response that mobilizes innate and adaptive immunity","volume":"22","author":"Sagoo","year":"2016","journal-title":"Nat Med"},{"key":"B300","doi-asserted-by":"publisher","first-page":"9050915","DOI":"10.1016\/j.nucmedbio.2012.05.003","article-title":"Characterization of 99mTc-labeled cytokine ligands for inflammation imaging via TNF and IL-1 pathways","volume":"39","author":"Liu","year":"2012","journal-title":"Nucl Med Biol"},{"key":"B301","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1021\/acschemneuro.6b00056","article-title":"In vivo imaging of human neuroinflammation","volume":"7","author":"Albrecht","year":"2016","journal-title":"ACS Chem Neurosci"},{"key":"B302","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.cct.2013.05.001","article-title":"A review of phase II trial designs for initial marker validation","volume":"36","author":"Mandrekar","year":"2013","journal-title":"Contemp Clin Trials"},{"key":"B303","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2017.04.005","article-title":"Should we stop saying \u201cglia\u201d and \u201cneuroinflammation\u201d?","author":"Masgrau","year":"2017","journal-title":"Trends Mol Med"},{"key":"B304","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc.2017.36","article-title":"Drugging the \u2018undruggable\u2019 cancer targets","volume":"17","author":"Dang","year":"2017","journal-title":"Nat Rev Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00557\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T22:39:04Z","timestamp":1693607944000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00557\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,4]]},"references-count":304,"alternative-id":["10.3389\/fimmu.2018.00557"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.00557","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,4]]},"article-number":"557"}}